Analyst Richard Hendriks, Ph.D., partners with pharmaceutical and biotech companies to discover the most effective ways of meeting their business goals. This encompasses a range of solutions from innovations in biotechnology to analytical assessments of recent treatment advances.
Qualitative analyses of citation and patent literature is the foundation of such endeavors, and Dr. Hendriks has specialized in this area for over 15 years with Nerac. During that time, he has gained significant industry and government insight. He has a Ph.D. in neuroscience from University of Melbourne, Australia, and a background in neuronal electrophysiology. During his research career, Dr. Hendriks received several grants and fellowships from the National Institutes of Health and the National Science Foundation. He was a principal investigator for early collaborative research with Sandoz that focused on neuronal receptor pharmacology for a compound that was eventually commercialized as Tropisetron. His subsequent research focused on the central nervous system and included an investigation into the role of potassium channels in embryonic neuronal migration as part of an investigation into potential cures for deafness during a research affiliation with Yale Medical School of New Haven, CT. Dr. Hendriks has authored several published articles and abstracts on physiology and electrophysiology.
He has also worked for the USPTO, successfully examining over 800 PCT patent applications, in the field of Medical Devices. As such, he has expertise in prior art searching, medical devices, claim structure, and the use of patent search engines. Overall, Dr. Hendriks’ areas of proficiency within Nerac include; intellectual property, medical devices, pharmacovigilance, toxicology, pharmacology, drug development, electrophysiology, bioengineering and neurotransmitters.